Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/1/26 Eli Lilly (LLY) retatrutide for Obesity Subscribers Only Subscribers Only Subscribers Only
10/1/26 Eli Lilly (LLY) retatrutide for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
9/30/26 Cyclo Therapeutics (CYTH) Trappsol Cyclo for Niemann-Pick Disease Type C Subscribers Only Subscribers Only Subscribers Only
9/23/26 Roche (RO) RG6299 for Immunoglobulin A (IgA) Nephropathy (Berger's Disease) Subscribers Only Subscribers Only Subscribers Only
9/22/26 Roche (RO) enicepatide for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/13/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update